SCHEMBL990845 — predicted protein targets

Predicted protein targets (top 9)

	gene	UniProt	supporting neighbours	confidence
▸	GRM5	P41594	16/20	0.56

▸	GRM4	Q14833	1/20	0.43

▸	HDAC6	Q9UBN7	1/20	0.43

▸	CNR2	P34972	1/20	0.43

▸	EGFR	P00533	1/20	0.43

▸	ERBB2	P04626	1/20	0.43

▸	MET	P08581	1/20	0.43

▸	KDR	P35968	1/20	0.43

▸	MERTK	Q12866	1/20	0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL992162	1.00	GRM5 (0.56)	GRM5GRM4HDAC6CNR2EGFR
SCHEMBL992297	0.90	GRM5 (0.58)	GRM5
SCHEMBL992298	0.89	CNR2 (0.48)	GRM5CNR2
SCHEMBL990819	0.89	GRM5 (0.46)	GRM5CNR2
SCHEMBL990196	0.89	CNR2 (0.48)	GRM5CNR2
SCHEMBL990171	0.89	GRM5 (0.46)	GRM5CNR2
2-Picolinic Acid SCHEMBL3631655	0.88	GRM5 (0.50)	GRM5
SCHEMBL990944	0.87	GRM5 (0.58)	GRM5CNR2
SCHEMBL990821	0.87	GRM5 (0.44)	GRM5
SCHEMBL1906015	0.87	GRM5 (0.58)	GRM5CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
WO-2011137206-A1	PREDICTIVE MARKERS USEFUL IN THE TREATMENT OF FRAGILE X SYNDROME (FXS)	NOVARTIS AG (CH)	2011-11-03	—	—	WO	disclosed
EP-2272509-A1	New Uses of metabotropic glutamate receptors	Novartis AG (CH)	2011-01-12	—	—	EP	disclosed